MarginsXMarginsX
Home › Markets › Health Care › LABT

Lakewood-Amedex Biotherapeutics Inc. (LABT)

LABT trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$0.2194
-22.31% on the day
Market cap
$520K
Nano cap
Revenue
New registrant: no annual report filed under this company yet
Net income
New registrant: no annual report filed under this company yet

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.

Profile

FieldValue
TickerLABT on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO yearNot reported by the screener
SEC CIK0002079272
SEC industry codePharmaceutical Preparations
Incorporated inNV

Financials

New registrant: no annual report filed under this company yet.

Warning signs

Cash runway
9.2 months
$2.6M cash at June 30, 2026
Share count, 1 year
No year-earlier count
Going-concern doubt
Yes
10-Q filed August 14, 2026
Insider net buying, 12 months
$0
Through September 30, 2026
SignFindingSource
Going concernStates substantial doubt about continuing as a going concern.
"These conditions raise substantial doubt about the Company's ability to continue as a going concern within one year after the date that the condensed financial statements are issued."
10-Q 2026-08-14
Cash and burn$2.6M cash; operating cash flow -$842K a quarter.Report 2026-06-30
Shares outstanding2,369,688 (2026-08-03).Cover page 2026-08-03
Reverse splits, 3 years1; latest 1-for-10 on 2026-06-22Source 2026-06-22
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 0 424B5 takedownsNone on EDGAR
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorCBIZ CPAs P.C., Tampa, Florida, United StatesPCAOB Form AP 2026-09-28
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q2 2026
2026-06-30
Not filed-$3.8M-$2.1M$2.6MNo debt tagsNeeds four quarters10-Q 2026-08-14
Q2 2026
2026-03-31
Not filed-$923K-$350K$12KNo debt tagsNeeds four quarters10-Q 2026-08-14
Q2 2026
2025-06-30
Not filed-$656K-$509K$1.3MNo debt tagsNeeds four quarters10-Q 2026-08-14
Q2 2026
2025-03-31
Not filed-$540K-$404K$477KNo debt tagsNeeds four quarters10-Q 2026-08-14

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document
REGISTRATION STATEMENT
S-12026-09-18
Latest quarterly / interim
QUARTERLY REPORT
10-Q2026-11-16
Latest current report
CURRENT REPORT
8-K2026-11-16
Latest proxy
DEFINITIVE ADDITIONAL MATERIALS
DEFA14A2026-08-10

Source: SEC EDGAR submissions feed, 47 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-28.2%
1 month-59.4%
3 months-88.0%
Year to dateNot enough price history
1 yearNot enough price history
From 52-week high-99.7%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
CDTCDT Equity Inc.$0.3770-5.84%$384K
SPRCSciSparc Ltd.$0.3307-10.62%$815K
OGENOragenics Inc.$0.1980-1.49%$893K
MTNBMatinas Biopharma Holdings Inc.$0.9270+3.00%$908K
GOVXGeoVax Labs Inc.$2.02+18.48%$1.1M
BDRXBiodexa Pharmaceuticals plc American Depositary Shs$2.24-6.28%$1.2M
ELABPMGC Holdings Inc.$1.66+5.06%$1.3M
KAPAKairos Pharma Ltd.$0.4069-10.30%$1.4M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier